Sabrina Chiara Cecere

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Sandro Pignata, Domenica Lorusso, Giovanni Scambia et al. · The Lancet Oncology · 2015 · 172 citations · Full text

Medicine, Oncology, Pharmacology +13

Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer

Michele Cioffi, Crescenzo D’Alterio, Rosa Camerlingo et al. · Scientific Reports · 2015 · 107 citations · Full text

Medicine, Cell Biology, Oncology +17

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari et al. · Gynecologic Oncology · 2019 · 106 citations · Full text

Medicine, Gynecology, Oncology +16

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

Domenica Lorusso, Gabriella Ferrandina, Nicoletta Colombo et al. · Gynecologic Oncology · 2019 · 96 citations

Medicine, Gynecology, Oncology +7

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study

Sandro Pignata, Giovanni Scambia, Alessandra Bologna et al. · Journal of Clinical Oncology · 2017 · 90 citations

Medicine, Gynecology, Oncology +13